beta-glucan

Phase 3Biologic

BBiotec Pharmacon ASA

beta-glucan is one of 145 biologic programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

144

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

LeukemiaActive, not recruiting

NeuroblastomaActive, not recruiting

Diabetic FootActive, not recruiting

LymphomaPhase 1

Active, not recruiting

LeukemiaPhase 1

Active, not recruiting

NeuroblastomaPhase 2

Active, not recruiting

Diabetic FootPhase 3

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

beta-glucan

BBiotec Pharmacon ASA

Phase 3

1 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Norvir

AbbVie

Preclinical

1 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Tafasitamab

Incyte

Preclinical

7 7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neuroblastoma3 trials

Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00089258·74 enrolled

Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00492167·45 enrolled

Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00037011

Leukemia1 trial

Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00087009·3 enrolled

Diabetic Foot1 trial

Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers

Completed·BBiotec Pharmacon ASA·Phase 3·NCT00632008·122 enrolled

Lymphoma1 trial

Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma

Completed·BBiotec Pharmacon ASA·Phase 1·NCT00533728·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for beta-glucan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — beta-glucan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for beta-glucan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biotec Pharmacon ASA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: BBiotec Pharmacon ASA

beta-glucan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neuroblastoma3 trials

Leukemia1 trial

Diabetic Foot1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News